Protalix BioTherapeutics (PLX) Current Assets (2010 - 2026)

Protalix BioTherapeutics' Current Assets history runs 17 years deep, the most recent figure standing at $86.4 million for Q1 2026.

• In Q1 2026, Current Assets rose 42.7% year-over-year to $86.4 million; the TTM figure through Mar 2026 stood at $86.4 million (up 42.7% YoY), while the FY2025 annual figure was $66.7 million, up 10.98% from the prior year.
• Current Assets was $86.4 million for Q1 2026 at Protalix BioTherapeutics, up from $66.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $86.4 million in Q1 2026 to a low of $44.9 million in Q4 2022.
• Historically, Current Assets has averaged $63.2 million across 5 years, with a median of $65.5 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Current Assets tumbled 48.19% in 2022, then soared 58.69% in 2023.
• A 5-year view of Current Assets shows it stood at $44.9 million in 2022, then soared by 55.82% to $69.9 million in 2023, then slipped by 14.09% to $60.1 million in 2024, then increased by 10.98% to $66.7 million in 2025, then rose by 29.52% to $86.4 million in 2026.
• The last three Current Assets figures came in at $86.4 million (Q1 2026), $66.7 million (Q4 2025), and $66.5 million (Q3 2025), per Business Quant data.